Feb 28 (Reuters) – Drugmaker Viatris forecast annual revenue above Wall Street estimates on Wednesday, banking on strong demand for its branded drugs such as Yupelri for lung disease and Breyna for asthma. The company said it expects 2024 revenue to be in the range of $15.25 billion to $15.75 billion, the midpoint of which […]